News

Chordate Medical presents interim report for Q1 2022

25 May, 2022

Chordate Medical Holding (publ) publishes its interim report for Q1 2022 on Friday, May 27th, 2022, at 08:30. On Monday, May 30th at 14:00, the company invites the public to a livestreamed teleconference with CEO Anders Weilandt. The conference is followed by a Q&A session. You can follow the conference via computer or mobile devices.

To register for the web conference, register via the following link: https://attese.gotowebinar.com/register/6856232777036844045

The number of places is limited, so we recommend registering well in advance to secure a place.

After the conference, a recording of the web conference will be available on the companys website www.chordate.com and on the Västra Hamnen Corporate Finance YouTube channel.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

 

Contact us

The information is handled according to our  privacy policy.